Interferon β-1a therapy for multiple sclerosis during pregnancy: an unresolved issue

Area of Science:

• Neurology
• Immunology
• Reproductive Medicine

Background:

• Multiple sclerosis (MS) management during pregnancy poses challenges due to potential risks to the fetus and mother.
• Interferon (INF) therapies are commonly used for MS but are generally contraindicated in pregnancy.
• Previous studies indicate withdrawal of INF therapy before or during gestation.

Observation:

• A 26-year-old woman with relapsing-remitting MS received weekly intramuscular INF-β 1a (Avonex).
• She continued this treatment throughout her entire pregnancy.
• No MS exacerbations or pregnancy complications were observed during treatment.

Findings:

• The patient experienced the longest documented exposure to INF-β 1a during pregnancy.
• Continuous INF-β 1a treatment did not result in adverse pregnancy-related outcomes or congenital anomalies in this case.
• The patient remained free from MS relapses throughout the pregnancy.

Implications:

• This case suggests that INF-β 1a may be a viable treatment option for select MS patients during pregnancy.
• Further research is warranted to confirm the safety and efficacy of extended INF-β 1a exposure in pregnant MS patients.
• This finding could influence clinical guidelines for managing multiple sclerosis in pregnant individuals.